Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Moore

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Nature|May 31, 2019
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Epidemiology and Infection|January 22, 2024
The predictive role of symptoms in COVID-19 diagnostic models: A longitudinal insightOlivia Bird, Eva P Galiza, David Neil Baxter, et al.
Nature|November 9, 2018
Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
Nature|May 31, 2019
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activityJoshi M Ramanjulu, G Scott Pesiridis, Jingsong Yang, et al.
The New England Journal of Medicine|June 30, 2021
Safety and Efficacy of NVX-CoV2373 Covid-19 VaccinePaul T Heath, Eva P Galiza, David N Baxter, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled TrialPaul T Heath, Eva P Galiza, David Neil Baxter, et al.
The Journal of Infection|August 9, 2025
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trialLeila Janani, Alasdair P S Munro, Annie Wright, et al.
Lancet (London, England)|December 5, 2021
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trialAlasdair P S Munro, Leila Janani, Victoria Cornelius, et al.
The Lancet. Infectious Diseases|May 13, 2022
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialAlasdair P S Munro, Shuo Feng, Leila Janani, et al.
The Journal of Infection|April 13, 2023
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]Xinxue Liu, Alasdair Ps Munro, Shuo Feng, et al.
The Journal of Infection|April 11, 2022
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trialXinxue Liu, Alasdair P S Munro, Shuo Feng, et al.
Pageof 7